Arnold, Shanna A.
Loomans, Holli A.
Ketova, Tatiana
Andl, Claudia D.
Clark, Peter E.
Zijlstra, Andries http://orcid.org/0000-0001-8460-8803
Funding for this research was provided by:
National Institutes of Health (CA9060625)
National Center for Advancing Translational Sciences (UL1-TR000445)
National Cancer Institute (CA009593, CA143081, CA040035)
National Institute of Diabetes and Digestive and Kidney Diseases (DK094900, DK091491)
Office of Research and Development (IK2BX002498)
Article History
Received: 24 March 2015
Accepted: 1 October 2015
First Online: 11 October 2015
Compliance with ethical standards
:
: This article does not contain any studies with animals performed by any of the authors.
: The authors have no competing interests to disclose.
: Despite improvements in the detection and treatment of bladder cancer (BCa), few advances have been made in predicting outcome and non-invasively monitoring disease progression. We show that the ED-A isoform of fibronectin and not total fibronectin is a prognostic urinary biomarker in BCa. Furthermore, the greatest discrimination with urinary ED-A occurs in lymph node negative patients where those with undetectable levels of urinary ED-A are 10 times more likely to survive 2 years following cystectomy compared to those with any detectable level of urinary ED-A.